Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL), along with associated arterial or venous thrombosis and pregnancy complications, including recurrent pregnancy loss. Therapeutic apheresis is performed in patients with treatment-resistant catastrophic APS (CAPS), which is characterized by multiple vascular occlusive events, usually affecting small vessels and developing over a short period of time. Approximately 30% of SLE patients have concurrent APS, and CAPS is reported to occur in about 1% of APS cases [1]. Diagnosis is typically based on the revised 2006 Sydney criteria (originally from the Sapporo criteria), but in 2023, a new classification system with higher specificity was proposed by the American College of Rheumatology and the European League Against Rheumatism [2].